Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug
ConclusionsACT-709478 exhibits good tolerability up to 100 mg once daily using an up-titration regimen and pharmacokinetic properties that support further clinical investigations. A weak induction of gastrointestinal cytochrome P450 3A4 activity was observed, unlikely to be of clinical relevance.ClinicalTrials.gov IdentifierNCT03165097.
Source: CNS Drugs - Category: Neurology Source Type: research
More News: Calcium | Electrocardiogram | Epilepsy | Gastroenterology | Headache | Laboratory Medicine | Migraine | Neurology | Study